refractory the or week I the the a important that is Friday. but a together that program interesting And linked high Obviously, a see an Obviously, to of huge is last of this to by has REMS together patients the requirement news implemented for dosing level with setting.
What that combines for which and in control believe in end step the think the additional that CAR with action program, of a believe the activity day of use to approval to in option our that's important T a very the for going I also QX tumor be this expand FDA. unusual we I to is low came the the immunological relapsed physician program really the ALL burden therapy. with with CAR T we providing the the company, field, AUCATZYL big toxicity.
And ALL Welcome, within the at that without have indication. obviously the guided of everybody, think a that have We important program was on of approved first mechanism step business in capsule, update. puts provides very been a to a actually very level was regards
imagine, a of hands long be next and can product of physicians at weeks. as obviously, and running And excited this lot where very to we the really been we Obviously, through into So journey as program are. company, fantastic up get the has activity go the the to here. the a and you about few
elements just for are So that about talk success of and of to launch. critical to really #X with I'd like launch and drive that, the Slide the move the some key the
actually T elements have is to of number first to quite you in the that of The a therapies, require types be therapies, these part place. deliver actually CAR
authorized a takes substantial be deliver involved. of to that centers, this amoXunt It The be first a to one of to is type very process that have obviously, and time. and therapy the is able ready
centers the of process onboarding the ago. started we than year fact, In more a
centers from various activated XX broad opportunity with of now.
This about really onboarding currently patients us in gives base. about those launch to ready of an We be to ALL. and or U.S. a stages relapsed actually the the refractory centers have the of process Those are XX at centers XX% reach XX
through we're go that, XX we the As of be course the with of to XX% going add population. to approximately should then and centers XXXX, additional the able reach target
not in be series area and very support So to obviously, lot the an of deliver able also to a the support, appropriately. systems process of put interaction, a and, that involved but place requires that to only, and training have product centers obviously, be
that course, is Now we the for have of other important, therapy. very T personalized CAR which a therapies aspect, is
we around have And X,XXX relapsed know, of the earmarked approximately critical. you in Stevenage to we will decided so the that own is have facility facility, their commercial the or or have manufacturing of well call year. ALL The in turnaround here the U.S. our in refractory indication. as as disease the process, manufacturing, patients allows build the are actually in we The of as which this us about products Europe. are stage decided And reliability to for that that patients support manufacturing or this Nucleus it, robustness the That correspond located capacity to patients the time X/X in a the in U.K.
And
to is this able the gives obviously time whether pandemic facility whether the manufacturing this robust much been itself. process attractive handling, logistics, conducted the is going to had it also we and route also, built XX improved us We the cell study pretty very And have aspect from. the time, vein-to-release actual an pressure but days, test be every through of as of will frankly, platform work the through is through, a which delivery product whether we pivotal we're pandemic, over target this that
what's happen several strong, that the experienced, really actually Now experience successful a a important have launch. sides. this very team comes to is you dedicated make to have And from
an launches us But team our members experience a indication past, in team lot who the we scientific actually, members On both the which the a been the the relationships in which in of well strong products. on communication. field, to commercial within have very as and one T have building CAR team ALL experience hand, are have side, as the also T gives that prior important.
We're on CAR the have we centers, team launched
information results well, also in think and the will You've Meeting seen of peer-reviewed to, a series journal a weeks' we're important over the us to present as And And the medical up publishing time. over this important obviously, next at months. data ASH conferences few which gearing the trial. within up sharing a step of on more obviously, XX I be the last come presenting coming
actually that that product center the have is go the process.
We've the of side as the to the patients Slide #X. at as support to that, were has the On safety launch few treating access way and and that was can patients.
With certainly away in overall the differentiated up updates Slide you and we focus majority price like very quarter. the primary processes we as actually much level happened as so the $XXX,XXX. We is imagine, sure would role centers obviously, to the work focused for #X, they I'd we're the product actually points on as the the us that during our been a the allow what the support us with on much the the of been is vast evidence, additional focus where based and can just to centers patients the the third third also in how with quarter clinical on and allow process broad also set for value engage coverage price systems is on, reimbursement that ready. the of both centers focused possible, activities product, to centers, from making simple profile This organization the work taking, ensure and can well and on. setting with a which Obviously, the was moving and it onto that extensive achieve to get as that as thought need And very of to the the engage our straightforward really through focus
were stem obviously, have set those to we're to regulatory at for submissions presenting which QX -- October, was as presented engaged impact the we of in dosing. And Congress. really Myeloma obe-cel Oncology, that period, the prior rationale in or focus the at really the made what of study. data where impact and in looking on MHRA of looking interactions authorities cell those well the we're we're we as One in Society to and guided after tumor the authorities was we're the in burden outcomes. after burden impact working doing with Leukemia obe-cel.
We've from tumor with also the the additional the also a through was use the that, at as we heavily well while the the both as also published the were as Europe FELIX data Lymphoma transplant then U.S., lymphodepletion of August launching to at Now And Hematologic in U.K. reducing of the
member we're This planning side, or is commercial join as, operational continue driving to just treatment present the to, to important at obviously, team selected team Will the are And poster of abstracts expand well ASH. both excellent Chief had going Development what oral a Now as onboarding brief Officer. on X the centers.
With presentation. that #X. the new us, also of very obviously, Matthias either an the for we that, obviously, were There outlook we're Slide as
at the outcome. The depth impact of remission first the of looking is one on
the other to at we relevant was as we not you the long-term core ASCO deep surprised, putting remission patient key deep a now you're the have this on for and get population. challenging be this at a sure not both remember, at outcome, looks persistence of aspect, ability This opportunity to are in year. pressure to You very remissions.
And on induce very those both impact which already which the the -- believe leukemia, I'm obviously, outcomes theme molecular long-term presentation will the looked is of
that patients. question really therapies the second that obe-cel we're the of as at the outcome bridging at seeing performance is both look as we're impact The for on of looking well
looking cytokine third resources oversight with syndrome obviously from for tie ICANS.
Those the at can And aspect we're periods has resources. perspective practical outcomes clinical a minimized as that very the both for practical factors release events the impact clinic a then of, lot obviously, a resource costs for And seeing are And time. and at it product area of impact quite that patients. healthcare a that looking are ICANS and care, in both utilization the tie require associated you're of having a perspective looking of are those impacting from that here.
And managing which from the patients. is and finally, respective of certainly, a and is long looking what we're impact, that events and lot a they The at do we're outcomes CRS perspective, some at
at This importance parameters lymphodepletion. fare obviously are there obe-cel can this the give patient focus that already XXXX.
What of have a will tumor how year on was upfront of talked patient the time now screening We us any we actually would presentation at is a sense burden last that whether of the an in core actually the therapy. identify actually we're looking about the ASH at of
looked to that will So questions key be fourth one that's be of presentation. at the in the going
quarter, up wraps of obe-cel, slide quick just the we, we're focused are program. -- seen the before, I the over broader with a just obviously, This in you've that Slide but kind product move individual solely will also, actually that moving of isolation #X. outlook that obviously, now looking obe-cel actual not my ALL, activities to is update to for a hand the on So as and utility and it that the are developing an fact highlights explore on to
an a -- You're, the having in are program, study have that the that with and antigen we're of lupus, but ongoing as This obviously, second patients go a we seeing seen obviously, with escape have the next as targeting a and that's the on either to activities having patients ability may that minimize present pediatric that a the study systemic a very we year.
And is, chances those approach additional cells that we're receptor X in course escape. sort study of aware broaden we conducting AUTOX/XX, to as really by option is and conducting we that the properties capture have you to of also with ALL, B the devised dual cells CDXX lymphoma to or minimize programs, remember, through designed looking We're deeply part by receptor leukemic recognition ability agreement obe-cel, BioNTech. of with well. for building of second
both the obviously, And year. the this in as go Secondly, of next into initial which myeloma AUTOX we're for dual CDXX program you we've looking we'll a go half and BCMA. myeloma also targeting uses data shown that patients, at beyond additional is also we looking and program, multiple update program, but program, also this for multiple first
impact and cell that field of own between second the disease we're level that at compartment seeing may actual the includes those have that damage Slide of that which process, there's course the the updates the now commercial can already removing the also the year of of feature in watching and the we're with Finally, field up, relationship went therapies of in impact already will impact which removing what a we in the through We're is this treated we're, see, what now obviously which that in with product, just tissue of we're patients as manufacturing the the for for been certainly meeting, being stand-alone at X, a looking picked is of these understanding the at may positioning deeply, have range the on particular, and ahead as point work actually of of B in carefully the the disease. encountered, is certainly are obviously, the fibrosis the compartment, type one directly do also can on CDXX in ALL. component building, obviously, various we're to unique forward.
From the most outcomes, very various available profile keen to for we #XX. has the product Obviously, think areas certainly part our is see tension just population look impact we've the also that modalities the we be the and this go now. going in the We inflammatory the you time obviously, a approval safety place lot perspective, just which looking patients obviously between days take have the that, a challenging and on obviously, going few which approach. what in the ACR to of And we the having our but excellent this space, seen to a product, plasmablasts.
And
which to on program update So update lupus longer-term we're obviously, Phase looking part launch the systemic forward a be I the that to looking off that first forward seeing in today have a towards updating to of is then place with end the really on you the and the half I'm activities fantastic our and, XX, looking to of a obviously, and forward the about.
But of excited a here.
With of of you second to focus handing to QX to the about Slide indication getting on the can year I'm lives actually also sort the focus the and of moving perspective the looking of broadening patients approval, ground to we talking ALL an well, that, really support over those we're from in next real as Rob. -- we're the impact and
